The Ledger

IDXX

Idexx Laboratories IncHealth Careinsider_universe

Last close $535.84Jun 28, 2026

Day −2.84%

Currently held

Agent 5 — Dip Buyer (Evolving)long
2 sh @ $532.86 · stop $490.23
+$5.95 unrealized
Agent 9 — Bear Equityshort
18 sh @ $532.86 · stop $612.79
-$53.55 unrealized

Everything we've seen

·Jun 29, 12:18 PMstreamnews
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock?
Investors need to pay close attention to IDXX stock based on the movements in the options market lately.
❖Jun 29, 10:05 AMnewsvia finnhub
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock?
Investors need to pay close attention to IDXX stock based on the movements in the options market lately.
?Jun 25, 10:11 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
IDXX is up 3.15% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven pop that might fade quickly. The macro context shows 10Y inflation expectations (T10YIE) printing 2.4σ below trend, which is constructive for long-duration growth names like IDXX (a high-multiple, defensive-growth compounder in veterinary diagnostics). Lower inflation expectations reduce discount rate pressure, supporting premium valuations. However, there are meaningful offsets: (1) 335 minutes remaining is actually substantial time — over 5.5 hours — which means there is also ample time for a fade or mean-reversion in an extended move; (2) no news catalyst means the move could be a large block trade or index rebalance flow that may have already exhausted itself; (3) IDXX is not in a classically rate-sensitive sector, so the macro tailwind is indirect rather than direct. The move is real and represents conviction from someone with size, but without a clear narrative driver or sector momentum signal, I lean toward mild continuation rather than strong follow-through. Probability set modestly above the 0.5 trigger threshold.
!Jun 25, 10:11 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
IDXX is up 3.15% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven pop that might fade quickly. The macro context shows 10Y inflation expectations (T10YIE) printing 2.4σ below trend, which is constructive for long-duration growth names like IDXX (a high-multiple, defensive-growth compounder in veterinary diagnostics). Lower inflation expectations reduce discount rate pressure, supporting premium valuations. However, there are meaningful offsets: (1) 335 minutes remaining is actually substantial time — over 5.5 hours — which means there is also ample time for a fade or mean-reversion in an extended move; (2) no news catalyst means the move could be a large block trade or index rebalance flow that may have already exhausted itself; (3) IDXX is not in a classically rate-sensitive sector, so the macro tailwind is indirect rather than direct. The move is real and represents conviction from someone with size, but without a clear narrative driver or sector momentum signal, I lean toward mild continuation rather than strong follow-through. Probability set modestly above the 0.5 trigger threshold.
!Jun 24, 9:17 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 5:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 5:32 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 5:20 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 4:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 4:35 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 4:21 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 3:49 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 2:48 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 2:37 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 2:19 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 1:48 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 1:36 PMsignal
Agent 6 — Options Momentum — insufficient_capital
?Jun 22, 12:12 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
IDXX is down 2.26% today, a meaningful move suggesting real selling pressure. The single headline is mildly positive ('small upgrade could have big impact'), which could provide some support and act as a headwind to further downside — but it hasn't arrested the decline so far mid-session. Macro context shows 5Y inflation expectations 1.5σ below trend, which is broadly neutral-to-slightly-negative for a premium-valued healthcare/diagnostics name like IDXX (lower inflation expectations can compress growth multiples modestly). With 214 minutes remaining there is ample time for continuation, but the positive news item introduces uncertainty about whether the selling exhausts itself into the afternoon. No clear reversal pattern is evident yet. On balance, the existing momentum and time remaining favor modest continuation downward, but conviction is limited given the constructive headline. Assigning just above 0.5 to reflect ordinary downward momentum with no strong reason to expect a full fade.
!Jun 22, 12:12 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
IDXX is down 2.26% today, a meaningful move suggesting real selling pressure. The single headline is mildly positive ('small upgrade could have big impact'), which could provide some support and act as a headwind to further downside — but it hasn't arrested the decline so far mid-session. Macro context shows 5Y inflation expectations 1.5σ below trend, which is broadly neutral-to-slightly-negative for a premium-valued healthcare/diagnostics name like IDXX (lower inflation expectations can compress growth multiples modestly). With 214 minutes remaining there is ample time for continuation, but the positive news item introduces uncertainty about whether the selling exhausts itself into the afternoon. No clear reversal pattern is evident yet. On balance, the existing momentum and time remaining favor modest continuation downward, but conviction is limited given the constructive headline. Assigning just above 0.5 to reflect ordinary downward momentum with no strong reason to expect a full fade.
❖Jun 22, 9:31 AMnewsvia finnhub
A Small Upgrade Could Have a Big Impact for IDEXX Customers
With a short percentage of shares outstanding of 2.76%, IDEXX Laboratories, Inc. (NASDAQ:IDXX) is among the 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue. On May 26, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced the expansion of its Fecal Dx antigen testing platform to include detection of taeniid tapeworm species, including Taenia and Echinococcus. The enhanced testing capability is […]
❖Jun 16, 2:01 PMnewsvia finnhub
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years
?Jun 10, 12:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
IDXX is down 1.81% intraday with no headline catalyst identified, suggesting the move is driven by broader market/sector flows rather than stock-specific news. The macro context shows a flattening yield curve (T10Y2Y 2.1σ below trend), which tends to pressure defensives and growth-oriented healthcare names like IDXX. However, at -1.81%, the move is meaningful but not extreme, and with 215 minutes remaining there is ample time for either continuation or mean reversion. No reversal signals are visible from the data provided, and the macro backdrop offers mild directional support for continued downside. With no strong reason to fade and the system's bounded risk profile, a borderline continuation call is warranted, but the lack of volume confirmation data and absence of any news catalyst prevent a higher conviction rating. Assigning 0.50 — a minimal lean toward continuation consistent with the default guidance when no strong reversal signal is present.
!Jun 10, 12:10 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
IDXX is down 1.81% intraday with no headline catalyst identified, suggesting the move is driven by broader market/sector flows rather than stock-specific news. The macro context shows a flattening yield curve (T10Y2Y 2.1σ below trend), which tends to pressure defensives and growth-oriented healthcare names like IDXX. However, at -1.81%, the move is meaningful but not extreme, and with 215 minutes remaining there is ample time for either continuation or mean reversion. No reversal signals are visible from the data provided, and the macro backdrop offers mild directional support for continued downside. With no strong reason to fade and the system's bounded risk profile, a borderline continuation call is warranted, but the lack of volume confirmation data and absence of any news catalyst prevent a higher conviction rating. Assigning 0.50 — a minimal lean toward continuation consistent with the default guidance when no strong reversal signal is present.
!Jun 10, 9:16 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 9:02 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 7:02 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 9, 6:04 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 9, 8:42 AMnewsvia finnhub
Is IDEXX Laboratories Stock Underperforming the Nasdaq?
IDEXX Laboratories has trailed the Nasdaq Composite over the past year, and analysts are fairly bullish on its future growth potential.
❖Jun 4, 11:30 AMnewsvia finnhub
Idexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
❖Jun 3, 5:19 PMnewsvia finnhub
IDEXX Parasite Test Expansion Links Zoonotic Risk And Valuation Debate
IDEXX Laboratories (NasdaqGS:IDXX) has expanded its Fecal Dx antigen testing to detect taeniid tapeworm in companion animals. The broadened panel includes medically significant Echinococcus species, a key zoonotic parasite of concern for veterinarians and public health officials. The update targets regions where taeniid tapeworm and Echinococcus are a growing focus for disease surveillance and prevention. IDEXX Laboratories, a veterinary diagnostics and software company, continues to build...
?Jun 2, 10:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
IDXX is down 1.52% with 290 minutes remaining — a moderate move with substantial time left in the session. The move is meaningful but not outsized (below the 2-5% threshold that would signal strong conviction flow). No IDXX-specific headline is driving today's action, which is neutral per guidance. The only news present is a Zoetis piece (a competitor/peer), which could reflect mild sector softness in animal health/diagnostics but is not directly actionable for IDXX. The macro backdrop shows a flattening yield curve (T10Y2Y at 0.42, 2σ below trend), which favors defensives — IDXX as a diagnostics/healthcare name sits in a defensive-adjacent sector that could see mild support rather than continued selling pressure, creating a slight headwind to continuation. With no clear catalyst driving the decline and a macro environment that is not overtly bearish for this sector, the move could easily fade or consolidate rather than extend. However, there is no strong positive reversal signal either. This resolves as a borderline read: modest downside momentum, no news catalyst, mixed macro — setting probability at exactly 0.5 to reflect genuine uncertainty while satisfying the threshold for a directional lean.
!Jun 2, 10:55 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
IDXX is down 1.52% with 290 minutes remaining — a moderate move with substantial time left in the session. The move is meaningful but not outsized (below the 2-5% threshold that would signal strong conviction flow). No IDXX-specific headline is driving today's action, which is neutral per guidance. The only news present is a Zoetis piece (a competitor/peer), which could reflect mild sector softness in animal health/diagnostics but is not directly actionable for IDXX. The macro backdrop shows a flattening yield curve (T10Y2Y at 0.42, 2σ below trend), which favors defensives — IDXX as a diagnostics/healthcare name sits in a defensive-adjacent sector that could see mild support rather than continued selling pressure, creating a slight headwind to continuation. With no clear catalyst driving the decline and a macro environment that is not overtly bearish for this sector, the move could easily fade or consolidate rather than extend. However, there is no strong positive reversal signal either. This resolves as a borderline read: modest downside momentum, no news catalyst, mixed macro — setting probability at exactly 0.5 to reflect genuine uncertainty while satisfying the threshold for a directional lean.
❖Jun 2, 3:45 AMnewsvia finnhub
Zoetis: Potential Deep Value Play With 60%+ Upside Potential Dividend Investors Should Watch
Zoetis stock fell 50% amid inflation and demand worries. Click here to read more on the stock's dividend safety, valuation, upside potential, and risks.
❖Jun 1, 12:06 AMnewsvia finnhub
Baron Asset Fund Q1 2026 Contributors, Detractors And Recent Activity
SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Read more here.
❖May 31, 7:08 PMnewsvia finnhub
Tracking Terry Smith's Fundsmith 13F Portfolio - Q1 2026 Update
Fundsmith's 13F portfolio value declined to $12.83B with holdings reduced from 37 to 34; the top five holdings comprise ~38% of assets. Read the full analysis now.
❖May 30, 7:02 AMnewsvia finnhub
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
IDEXX Laboratories (NASDAQ:IDXX) President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company’s innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics. Erickson, who recently b
?May 29, 9:21 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
IDXX is up 3.09% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm: (1) At 385 minutes remaining this is actually very early in the session, meaning there is ample time for both continuation AND reversal — not a late-day momentum lock-in scenario. (2) The macro backdrop shows T10Y3M elevated at 1.8σ above trend, which is mildly risk-positive (steepening curve) but IDXX as a veterinary diagnostics name is not a primary beneficiary of yield curve dynamics. (3) No news catalyst means the move could be program-driven or index rebalancing, which may have already completed. (4) A 3%+ move without a clear catalyst in a defensive-growth name like IDXX has some fade risk as price discovery occurs through the day. Balancing the momentum signal against the lack of a sustaining catalyst and the early session timing (giving plenty of time for fade), a modest continuation probability is appropriate. The bounded downside via the -1.5% stop supports taking the trade at this level.
!May 29, 9:21 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
IDXX is up 3.09% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm: (1) At 385 minutes remaining this is actually very early in the session, meaning there is ample time for both continuation AND reversal — not a late-day momentum lock-in scenario. (2) The macro backdrop shows T10Y3M elevated at 1.8σ above trend, which is mildly risk-positive (steepening curve) but IDXX as a veterinary diagnostics name is not a primary beneficiary of yield curve dynamics. (3) No news catalyst means the move could be program-driven or index rebalancing, which may have already completed. (4) A 3%+ move without a clear catalyst in a defensive-growth name like IDXX has some fade risk as price discovery occurs through the day. Balancing the momentum signal against the lack of a sustaining catalyst and the early session timing (giving plenty of time for fade), a modest continuation probability is appropriate. The bounded downside via the -1.5% stop supports taking the trade at this level.
❖May 27, 5:56 PMnewsvia finnhub
IDEXX Laboratories (IDXX) Embeds an Early Kidney Disease Detector Into Its Most Popular Test Profile
IDEXX Laboratories, Inc. (NASDAQ:IDXX) is one of the best medical technology stocks to buy right now. On May 19, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced that its SDMA kidney biomarker will be built directly into Catalyst CLIPs. Catalyst CLIPs is the most widely used point-of-care chemistry profiles on the company’s Catalyst platform. IDEXX said this integration […]
❖May 27, 9:27 AMnewsvia finnhub
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
IDEXX Laboratories, Inc. (IDXX) Stifel Jaws & Paws Conference 2026 May 27, 2026 10:55 AM EDTCompany ParticipantsMichael Erickson - CEO, President &...
❖May 26, 8:05 AMnewsvia finnhub
Is Wall Street Bullish or Bearish on IDEXX Laboratories Stock?
Although IDEXX Laboratories has lagged the broader market over the past year, Wall Street analysts remain fairly bullish about the company’s long-term growth prospects.
!May 26, 7:01 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖May 26, 7:00 AMnewsvia finnhub
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
WESTBROOK, Maine, May 26, 2026--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.
!May 22, 6:00 PMsignal
Agent 6 — Options Momentum — insufficient_capital
?May 19, 6:01 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 4: close $546.38 < MA150 $641.64 (-14.8%), MA falling, 29.0% off 52w high, vol 1.89× avg
?May 19, 11:40 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
IDXX is up 1.70% today, a moderate but not outsized intraday move. There are no recent headlines to explain the move, but absence of news is not disqualifying — this likely reflects quiet accumulation or broad market lift. With 245 minutes remaining (over 4 hours), there is ample time for continuation into the close, which is a positive factor. However, the macro context is a mild headwind: 10-year inflation expectations (T10YIE) are running 2.4σ above trend at 2.48, which pressures long-duration assets and growth-oriented sectors. IDXX, as a high-multiple diagnostics/veterinary company, carries meaningful duration sensitivity, so elevated real rate expectations could dampen momentum. The move itself is below the 2% threshold that would signal strong institutional conviction. Balancing moderate momentum and ample time against a macro environment that is mildly unfavorable for this type of name, I assign a slight lean toward continuation but without high conviction.
!May 19, 11:40 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
IDXX is up 1.70% today, a moderate but not outsized intraday move. There are no recent headlines to explain the move, but absence of news is not disqualifying — this likely reflects quiet accumulation or broad market lift. With 245 minutes remaining (over 4 hours), there is ample time for continuation into the close, which is a positive factor. However, the macro context is a mild headwind: 10-year inflation expectations (T10YIE) are running 2.4σ above trend at 2.48, which pressures long-duration assets and growth-oriented sectors. IDXX, as a high-multiple diagnostics/veterinary company, carries meaningful duration sensitivity, so elevated real rate expectations could dampen momentum. The move itself is below the 2% threshold that would signal strong institutional conviction. Balancing moderate momentum and ample time against a macro environment that is mildly unfavorable for this type of name, I assign a slight lean toward continuation but without high conviction.
?May 18, 12:20 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
IDXX (IDEXX Laboratories) is a high-quality, dominant player in veterinary diagnostics with strong recurring revenue, historically resilient margins, and a durable competitive moat. The 10.6% pullback from the 30-day high occurs in the absence of any identifiable company-specific negative news or SEC filings, suggesting the drop is more likely attributable to macro-driven sector rotation or broad market pressure. However, the elevated 5-year inflation expectations (T5YIE at 2.7, 2.5σ above trend) create a headwind for high-multiple growth/quality stocks like IDXX, as rising real rate expectations compress valuations for companies trading at premium multiples.
?May 18, 11:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
IDXX is up 2.60% intraday with no attributable headline, suggesting institutional or systematic buying rather than a news-driven spike that could quickly fade. The move has real size behind it. However, several factors temper conviction: (1) 280 minutes remaining is actually substantial time — roughly the full afternoon session — which increases the chance of mean reversion before the 3:45 ET cutoff rather than a clean continuation; (2) the macro backdrop shows elevated 5-year inflation expectations (T5YIE at 2.5σ above trend), which is a headwind for high-multiple growth/healthcare names like IDXX as rate-sensitive discount factors work against them; (3) no sector catalyst or news flow to anchor continued buying pressure; (4) a 2.60% move in a name like IDXX is meaningful and may already represent most of the day's institutional rebalancing. Balancing the momentum signal (real flow, no obvious fade trigger) against the macro drag and long time window, this is a marginal continuation call. Probability sits just above the 0.5 threshold — there is no strong reason to expect a reversal, but the setup lacks clear continuation pressure.
!May 18, 11:05 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
IDXX is up 2.60% intraday with no attributable headline, suggesting institutional or systematic buying rather than a news-driven spike that could quickly fade. The move has real size behind it. However, several factors temper conviction: (1) 280 minutes remaining is actually substantial time — roughly the full afternoon session — which increases the chance of mean reversion before the 3:45 ET cutoff rather than a clean continuation; (2) the macro backdrop shows elevated 5-year inflation expectations (T5YIE at 2.5σ above trend), which is a headwind for high-multiple growth/healthcare names like IDXX as rate-sensitive discount factors work against them; (3) no sector catalyst or news flow to anchor continued buying pressure; (4) a 2.60% move in a name like IDXX is meaningful and may already represent most of the day's institutional rebalancing. Balancing the momentum signal (real flow, no obvious fade trigger) against the macro drag and long time window, this is a marginal continuation call. Probability sits just above the 0.5 threshold — there is no strong reason to expect a reversal, but the setup lacks clear continuation pressure.
?May 18, 9:25 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, making it fundamentally sound. The 12.7% drop appears macro/sector-driven rather than company-specific — Health Care is the second-weakest sector over the 30-day window (rank 10 of 11), down ~13.87pts vs SPY, suggesting IDXX was caught in a broad sector rotation rather than suffering an idiosyncratic impairment. No negative news, SEC filings, or insider sales provide a confirmed bearish catalyst, leaving the cause of the dip ambiguous but consistent with sector-wide pressure.
!May 18, 9:25 AMsignalseverity 0.13
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, making it fundamentally sound. The 12.7% drop appears macro/sector-driven rather than company-specific — Health Care is the second-weakest sector over the 30-day window (rank 10 of 11), down ~13.87pts vs SPY, suggesting IDXX was caught in a broad sector rotation rather than suffering an idiosyncratic impairment. No negative news, SEC filings, or insider sales provide a confirmed bearish catalyst, leaving the cause of the dip ambiguous but consistent with sector-wide pressure.
?May 18, 8:54 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
IDXX is a high-quality veterinary diagnostics compounder with durable recurring revenue, strong moats in its IDEXX 360 platform, and historically resilient demand. The 12.7% pullback from the 30-day high appears attributable to macro pressure rather than company-specific deterioration, as no negative headlines or SEC filings are present in the evidence window. However, elevated 5-year breakeven inflation at 2.5σ above trend suggests persistent rate/discount-rate headwinds that disproportionately compress high-multiple growth stocks like IDXX, limiting near-term rebound conviction.
!May 18, 8:54 AMsignalseverity 0.13
Agent 4 — Dip Buyer (Frozen) — dip_skipped
IDXX is a high-quality veterinary diagnostics compounder with durable recurring revenue, strong moats in its IDEXX 360 platform, and historically resilient demand. The 12.7% pullback from the 30-day high appears attributable to macro pressure rather than company-specific deterioration, as no negative headlines or SEC filings are present in the evidence window. However, elevated 5-year breakeven inflation at 2.5σ above trend suggests persistent rate/discount-rate headwinds that disproportionately compress high-multiple growth stocks like IDXX, limiting near-term rebound conviction.
?May 16, 6:35 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $6.08 cash available; close=$528.79.
?May 16, 10:05 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is down 12.7% from its 30-day high at $528.79, which on the surface looks like a dip-buying opportunity for a quality compounder in veterinary diagnostics. However, the evidence base is critically sparse: no recent news headlines, no SEC filings, no insider activity, and no options flow data. Without knowing the catalyst for the decline, there is no basis to distinguish a valuation reset from a fundamental deterioration. The macro backdrop adds further caution: today's broad market is under pressure (SPY -1.20%, IWM -2.41%), VIX is at the 50th percentile (neutral but not supportive of aggressive dip buying), and the 10Y at 4.47% remains near the structural headwind threshold of ~4.5%. Elevated 5-year breakeven inflation (T5YIE at 2.7, 2.5σ above trend) suggests rates could stay higher for longer, which is a multiple-compression risk for a high-P/E name like IDXX. The 2s10s curve is positively sloped (+0.47pp), which is not recessionary but does not provide a 'flight to quality' tailwind. With no earnings catalyst visible, no insider buying signal, and no options flow to suggest informed accumulation, the risk/reward for a 90-day swing trade is unfavorable. The absence of any confirming signal in a declining tape makes this a pass.
?May 16, 9:00 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
IDXX is a high-quality veterinary diagnostics compounder with durable recurring revenue, strong moats in its IDEXX 360 platform, and historically resilient demand. The 12.7% pullback from the 30-day high appears attributable to macro pressure rather than company-specific deterioration, as no negative headlines or SEC filings are present in the evidence window. However, elevated 5-year breakeven inflation at 2.5σ above trend suggests persistent rate/discount-rate headwinds that disproportionately compress high-multiple growth stocks like IDXX, limiting near-term rebound conviction.
?May 16, 8:58 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
?May 15, 6:37 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
?May 15, 6:33 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
?May 15, 6:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
?May 15, 6:15 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
?May 15, 3:38 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
!May 15, 3:38 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
✓May 14, 9:36 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
IDXX is a high-quality veterinary diagnostics franchise with recurring revenue, strong moats, and historically resilient fundamentals — no headlines or SEC filings indicate any idiosyncratic deterioration driving this 12% pullback. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%, VXX -2.54%), suggesting the drop is not macro-contagion-driven but rather reflects earlier sector rotation or profit-taking. However, elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) create a headwind for premium-valued, low-yield growth names like IDXX, which compress on higher discount rates.
?May 14, 9:35 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, suggesting the company itself remains fundamentally sound. However, the 12% drop from its 30-day high occurs without any available news or filings to explain the move, which is a yellow flag — the absence of context cuts both ways, but idiosyncratic declines of this magnitude without visible macro stress (indices are broadly up 0.6-0.8% today) imply possible unreported negative catalysts such as earnings guidance revision or sector-specific headwinds. The elevated 5-year inflation breakeven (T5YIE at 2.7, 2.5σ above trend) adds a valuation compression risk for high-multiple growth names like IDXX.
?May 14, 9:34 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
IDXX is a high-quality, competitively moated veterinary diagnostics company with recurring revenue streams and strong historical fundamentals. The 12% pullback from the 30-day high appears to reflect macro-driven multiple compression rather than any identifiable company-specific deterioration, as there are no recent negative filings or news headlines. However, elevated 5-year inflation expectations (2.7, 2.5σ above trend) create a headwind for high-multiple growth stocks like IDXX, which typically trades at a premium valuation and is sensitive to discount rate pressure.
?May 14, 9:34 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
?May 14, 9:33 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
IDXX is a high-quality, competitively moated veterinary diagnostics company with recurring revenue streams and strong historical fundamentals. The 12% pullback from the 30-day high appears to reflect macro-driven multiple compression rather than any identifiable company-specific deterioration, as there are no recent negative filings or news headlines. However, elevated 5-year inflation expectations (2.7, 2.5σ above trend) create a headwind for high-multiple growth stocks like IDXX, which typically trades at a premium valuation and is sensitive to discount rate pressure.
?May 14, 9:33 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
?May 14, 9:26 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
IDXX is a high-quality, competitively moated veterinary diagnostics company with recurring revenue streams and strong historical fundamentals. The 12% pullback from the 30-day high appears to reflect macro-driven multiple compression rather than any identifiable company-specific deterioration, as there are no recent negative filings or news headlines. However, elevated 5-year inflation expectations (2.7, 2.5σ above trend) create a headwind for high-multiple growth stocks like IDXX, which typically trades at a premium valuation and is sensitive to discount rate pressure.
✓May 14, 9:24 PMdecisionacted
Agent 9 — Bear Equity — entry
Stage 4: close $532.86 < MA150 $643.35 (-17.2%), MA falling, 30.8% off 52w high, vol 1.24× avg
?May 14, 9:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
IDXX is a high-quality veterinary diagnostics franchise with durable recurring revenue and strong competitive moats, so no fundamental deterioration is evident from available evidence. However, the 12% drop from the 30-day high with zero supporting news or recent filings creates significant uncertainty — the absence of headlines makes it impossible to distinguish between a healthy technical pullback and an undisclosed idiosyncratic catalyst. While broad market tone today is constructive (SPY +0.79%, VXX -2.54%), the elevated T5YIE at 2.5σ above trend signals persistent inflation expectations that compress multiples on premium-valued growth names like IDXX, which historically trades at a significant P/E premium.
?May 12, 6:01 PMdecisionconsidered
Agent 9 — Bear Equity — considered
Stage 4: close $534.32 < MA150 $644.66 (-17.1%), MA falling, 30.6% off 52w high, vol 0.91× avg
?May 12, 2:09 PMdecisionconsidered
Agent 9 — Bear Equity — considered
Stage 4: close $537.92 < MA150 $644.68 (-16.6%), MA falling, 30.1% off 52w high, vol 0.09× avg

← Back to dashboard